Molecular Excipient

75.0 -3.0 1 2 68.0 1 0.5
Present in 98 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
GRIN1 Glutamate receptor ionotropic, NMDA 1 Ion Channel / Lgic

Clinical Trials

This compound has been an intervention in the following clincial trials (per
Code Date Title Phase Status
NCT02348775 2014-11-01 Glutathione and Function in HIV Patients Phase 1 Recruiting
NCT02348762 2014-11-01 Energetics and Function in Older Humans Phase 1 Recruiting
NCT02064881 2014-06-01 Efficacy Study of Metformin Glycinate on Postprandial Lipemia Phase 2/Phase 3 Not Yet Recruiting
NCT02108691 2014-05-01 Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight Phase 2/Phase 3 Not Yet Recruiting
NCT02128971 2014-04-01 A Study to Compare the Gastrointestinal Tolerability of FerrochelĀ®, SumalateĀ®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo Phase 2 Recruiting
NCT01720316 2012-12-01 Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders Phase 2 Enrolling By Invitation
NCT01417481 2012-03-01 Effect of Glycine in Cystic Fibrosis Phase 2 Terminated
NCT01501942 2012-02-01 Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma Phase 2 Completed
NCT01560481 2011-12-01 Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers Phase 1 Completed
NCT01386671 2011-08-01 Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Phase 3 Active, Not Recruiting
NCT01425463 2011-03-01 A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects Phase 3 Completed
NCT01913808 2011-01-01 Comparing Intravenous and Oral Iron in Postoperative Anemia Phase 4 Completed
NCT01355198 2010-08-01 Role of HIV on Glutathione Synthesis and Oxidative Stress Phase 1 Completed
NCT01116310 2010-04-01 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Phase 4 Recruiting
NCT00913692 2009-06-01 A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis Phase 2 Terminated
NCT00929370 2008-07-01 A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam. Phase 1 Terminated
NCT00575848 2007-12-01 Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia Phase 1 Terminated
NCT01031927 2007-06-01 N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD) Phase 2 Completed
NCT00133406 2006-06-01 Long-term Impact and Intervention for Diarrhea in Brazil Phase 3 Recruiting
NCT00291226 2006-03-01 Glycine vs Placebo for the Schizophrenia Prodrome Phase 2/Phase 3 Completed
NCT00133562 2004-08-01 HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition Phase 3 Withdrawn
NCT00338221 2004-08-01 Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition Phase 3 Withdrawn
NCT00338598 2003-06-01 Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism Phase 2 Active, Not Recruiting
NCT00268749 2002-07-01 Glycine Treatment of Prodromal Symptoms Phase 2 Completed
NCT00005658 2000-05-01 Glycine to Treat Psychotic Disorders in Children Phase 2 Completed
NCT00222235 2000-01-01 Adjunctive Treatment for Decreasing Symptoms of Schizophrenia Phase 2/Phase 3 Completed
NCT00000372 1998-03-01 Glycine and D-Cycloserine in Schizophrenia Phase 3 Withdrawn

(Browse) Purchasable Analogs in ZINC


Route Formulation Per Unit Dose
Im - Iv - Sc Powder, For Injection Solution
Im - Sc Powder, For Injection Solution
Intradermal Powder, For Injection Solution 0.05%
Intramuscular Injectable 3.22%
Intramuscular Injection 1.13%
Intramuscular Powder, For Injection Solution 4%
Intramuscular Powder, For Injection Solution, Lyophilized 2.76%
Intravenous Powder, For Injection Solution
Intravenous Powder, For Injection Solution, Lyophilized 1.5%
Intravenous Solution, Liposome, Injection 0.38%
Iv(infusion) Emulsion, Injection 20%
Iv(infusion) Powder, For Injection Solution 0.38%
Iv(infusion) Powder, For Injection Solution, Lyophilized 20%
Iv(infusion) Solution, Injection 0.42%
Oral Capsule 25MG
Oral Capsule, Delayed Action 25MG
Oral Capsule, Soft Gelatin 6.22MG
Oral Powder, For Oral Suspension 0.1%
Oral Powder, For Solution 9.08%
Oral Powder, For Suspension 1%
Oral Solution 5%
Oral Suspension 2%
Oral Suspension, Drops
Oral Tablet 163.31MG
Oral Tablet (immed./comp. Release), Uncoated, Chewable 200MG
Oral Tablet, Orally Disintegrating 20MG
Rectal Solution 5%
Respiratory (inhalation) Powder, For Inhalation 0.01%
Subcutaneous Injectable 0.14%
Subcutaneous Powder, For Injection Solution 2.4%
Subcutaneous Powder, For Injection Solution, Lyophilized 2.76%

More Information

Usage Over Time